2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor antagonists

US11304946B2 · kind B2 · utility

Assignees

• BAYER HEALTHCARE LLC · DE
• Bayer Pharma Aktiengesellschaft · DE
• Deutsches Krebsforschungszentrum · DE

Inventors

• Julien LEFRANC · Berlin, DE
• Norbert Schmees · Berlin, DE
• Ulrike Röhn · Berlin, DE
• Ludwig Zorn · Berlin, DE
• Judith Günther · Berlin, DE
• Ilona GUTCHER · Berlin, DE
• Lars Röse · Berlin, DE
• Benjamin Bader · Berlin, DE
• Detlef STÖCKIGT · Potsdam, DE
• Michael Platten · Heidelberg, DE

Key dates

• Filing date: Nov 16, 2018
• Grant date: Apr 19, 2022
• Expiry date: Dec 9, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D413/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention covers 2-hetarylpyrimidine-4-carboxamide compounds of general formula (I): in which X, Y, Z, R1, R2 and R4 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.